What This Top Dividend Portfolio Is Holding Now: GlaxoSmithKline plc, Royal Dutch Shell Plc And Antofagasta plc

GlaxoSmithKline plc (LON:GSK), Royal Dutch Shell Plc (LON:RDSB) and Antofagasta (LON:ANTO) are favoured holdings of Merchants Trust plc (LON:MRCH).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Merchants Trust (LSE: MRCH) has delivered 33 consecutive years of dividend increases, and carries a trailing yield of 4.8%. Picking great dividend shares has helped Merchants outperform the FTSE All-Share Index over the past three, five and 10 years.

Heavyweight high yielder GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), biggest holding and top yielder Royal Dutch Shell (LSE: RDSB) and new buy Antofagasta (LSE: ANTO) catch my eye in Merchants’ portfolio.

GlaxoSmithKline

Top FTSE 100 pharmaceuticals firm GlaxoSmithKline still does blockbuster drugs, but Merchants likes the way the company has been consolidating its global leadership positions in vaccines and consumer health, where there are “scale advantages” and “limited risk from generic competition”.

Earlier this month, Glaxo’s management set out its expectations for the reconfigured group. The Board anticipates an earnings decline in the current year at a percentage rate in the high teens, but expects to deliver a compound annual growth rate of mid-to-high single digits over the five-year period 2016-2020.

Management intends to peg the dividend at 80p a share this year and for the next two years. The payout equates to an annual yield of 5.5% for buyers of the shares at the current price of 1,442p. There’ll also be an additional 20p special dividend this year. From 2018, the prospects for dividend increases look good, if management delivers the mid-to-high single digits earnings growth it expects.

Royal Dutch Shell

Like Glaxo, oil supermajor Shell has put a near-term dividend increase on hold. The company has said it intends to pay an unchanged $1.88 a share this year — which may extend to next year, with management guiding on “at least that amount in 2016”.

At current exchange rates, the dollar dividend translates into a sterling payout of 121.3p, giving a yield of 6.1% for buyers of the shares at the current price of 2,000p.

The reason for the temporary halt to a dividend increase is Shell’s agreed £47bn acquisition of BG Group, announced last month. This deal is set to cement Shell’s leading position in the global LNG market and give the company a significant stake in attractive Brazilian assets. That should be good for shareholders’ dividends in the long run, and Merchants Trust is “supportive of the rationale for this deal”.

Antofagasta

Merchants has taken a new position in low-cost copper producer Antofagasta, explaining:

“Copper is an attractive commodity as supply is limited and increasingly expensive to develop whilst demand is broadly spread. Over time supply constraints should lead to a price recovery from depressed levels. The company has one of strongest balance sheets in the sector and is reasonably priced”.

Antofagasta’s dividend yield is a lowly 1.75% in the current subdued environment, but the company has a history of regularly returning excess capital to shareholders via special dividends when business is booming. At the current depressed share price of 775p, the kind of payouts we’ve seen on occasions in the past — and may see again in the future when the copper price recovers — would equate to a yield of 8%-9% during those years.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 dirt cheap FTSE 100 and FTSE 250 growth shares to consider!

Looking for great growth and value shares right now? These FTSE 100 and FTSE 250 shares could offer the best…

Read more »

Investing Articles

No savings? I’d use the Warren Buffett method to target big passive income

This Fool looks at a couple of key elements of Warren Buffett's investing philosophy that he thinks can help him…

Read more »

Investing Articles

This FTSE 100 hidden gem is quietly taking things to the next level

After making it to the FTSE 100 index last year, Howden Joinery Group looks to be setting its sights on…

Read more »

Investing Articles

A £20k Stocks and Shares ISA put into a FTSE 250 tracker 10 years ago could be worth this much now

The idea of a Stocks and Shares ISA can scare a lot of people away. But here's a way to…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

What next for the Lloyds share price, after a 25% climb in 2024?

First-half results didn't do much to help the Lloyds Bank share price. What might the rest of the year and…

Read more »

Investing Articles

I’ve got my eye on this FTSE 250 company

The FTSE 250's full of opportunities for investors willing to do the search legwork, and I think I've found one…

Read more »

Investing Articles

This FTSE 250 stock has smashed Nvidia shares in 2024. Is it still worth me buying?

Flying under most investors' radars, this FTSE 250 stock has even outperformed the US chip maker year-to-date. Where will its…

Read more »

Investing Articles

£11k stashed away? I’d use it to target a £1,173 monthly passive income starting now

Harvey Jones reckons dividend-paying FTSE 100 shares are a great way to build a long-term passive income with minimal effort.

Read more »